Literature DB >> 10529882

Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997.

R N Jones1, K C Kugler, M A Pfaller, P L Winokur.   

Abstract

Urinary tract infection (UTI) is common and involves pathogens with changing susceptibility patterns. The SENTRY Antimicrobial Surveillance Program evaluates international pathogen incidence patterns to detect and manage the emergence of resistant strains. We describe the antimicrobial resistance patterns among 1617 pathogens recovered from UTIs during the third-quarter of 1997 in North America (United States and Canada), as part of this worldwide program. The isolates were tested against more than 50 antimicrobial agents (20 reported) by reference broth microdilution methods, and selected isolates were characterized by pulsed-field gel electrophoresis (PFGE) and automated ribotyping. The five most frequently isolated species were Escherichia coli (48.6%), Enterococcus spp. (13.7%), Klebsiella spp. (12.0%), Pseudomonas aeruginosa (6.2%), and Enterobacter spp. or Proteus mirabilis (3.8% each). For each nation, imipenem and cefepime produced the widest spectrum of coverage among the beta-lactams and amikacin was best among the aminoglycosides. For Gram-negative species, high resistance among beta-lactam antimicrobial agents was noted especially for various penicillins against E. coli (37.9% to 42.8%) and for the cephalosporins tested against enterococci (99.4% and 100%). Approximately 7.0% of enterococci in the USA were vancomycin-resistant (88% with Van A). P. aeruginosa provided the most consistent levels of resistance, but the following agents were most active against these organisms: amikacin (96.6 to 97.4% susceptible), tobramycin (89.5 to 100.0%), piperacillin/tazobactam (89.5 to 100.0%), piperacillin (89.5 to 96.6%), imipenem (89.7 to 92.1%), cefepime (77.6 to 89.7%), and ceftazidime (82.9 to 86.2%). E. coli (2.2 to 2.7%), K. pneumoniae (6.2 to 6.4%), and a single Enterobacter cloacae strain produced extended-spectrum beta-lactamases; and five other Enterobacter spp. were likely to have expressed chromosomally mediated (Amp C) Stably derepressed cephalosporinases with associated resistance to ceftazidime (16.7 to 21.2% resistance). These data demonstrated that several UTI isolates in SENTRY hospitals have high levels of resistance to various classes of antimicrobial agents with little evidence of clonal dissemination.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10529882     DOI: 10.1016/s0732-8893(98)00158-8

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  24 in total

1.  Emerging extended-spectrum beta-lactamases in Proteus mirabilis.

Authors:  Laura Pagani; Roberta Migliavacca; Lucia Pallecchi; Cecilia Matti; Ernesto Giacobone; Gianfranco Amicosante; Egidio Romero; Gian Maria Rossolini
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

Review 2.  Epidemiology, treatment and prevention of healthcare-associated urinary tract infections.

Authors:  F M E Wagenlehner; Mete Cek; Kurt G Naber; Hiroshi Kiyota; Truls E Bjerklund-Johansen
Journal:  World J Urol       Date:  2011-09-07       Impact factor: 4.226

3.  Multidrug-resistant urinary tract isolates of Escherichia coli: prevalence and patient demographics in the United States in 2000.

Authors:  D F Sahm; C Thornsberry; D C Mayfield; M E Jones; J A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

4.  Urinary tract infections in children < 2 years of age hospitalized in a tertiary medical center in Southern Israel: epidemiologic, imaging, and microbiologic characteristics of first episode in life.

Authors:  David Shaki; Gabriel Hodik; Siham Elamour; Raouf Nassar; Eyal Kristal; Ron Leibovitz; Amir Horev; Eugene Leibovitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-01-13       Impact factor: 3.267

Review 5.  Gatifloxacin.

Authors:  C M Perry; J A Barman Balfour; H M Lamb
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

6.  Development of a panel of recombinase polymerase amplification assays for detection of common bacterial urinary tract infection pathogens.

Authors:  B Raja; H J Goux; A Marapadaga; S Rajagopalan; K Kourentzi; R C Willson
Journal:  J Appl Microbiol       Date:  2017-08       Impact factor: 3.772

7.  Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States.

Authors:  James A Karlowsky; Laurie J Kelly; Clyde Thornsberry; Mark E Jones; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  James A Karlowsky; Mellany K Weaver; Clyde Thornsberry; Michael J Dowzicky; Mark E Jones; Daniel F Sahm
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

9.  Approach to a patient with urosepsis.

Authors:  Om Prakash Kalra; Alpana Raizada
Journal:  J Glob Infect Dis       Date:  2009-01

Review 10.  Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections.

Authors:  Culley Carson; Kurt G Naber
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.